MedTrace Logo

Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain

NCT02447848 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2017-10-19

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and efficacy of sufentanil tablet (ST) 30 mcg in the management of moderate-to-severe acute pain in patients in an emergency room (ER) setting.

Conditions

  • Moderate-to-severe Acute Pain

Interventions

DRUG

sufentanil sublingual 30 mcg tablet

Sponsors & Collaborators

  • U.S. Army Medical Research and Development Command

    collaborator FED

  • Talphera, Inc

    lead INDUSTRY

Principal Investigators

  • Pamela P. Palmer, MD, PhD · Talphera, Inc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-06-30
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02447848 on ClinicalTrials.gov